BR112014010295A2 - métodos e composições para o tratamento de vírus de hepatite c - Google Patents

métodos e composições para o tratamento de vírus de hepatite c

Info

Publication number
BR112014010295A2
BR112014010295A2 BR112014010295A BR112014010295A BR112014010295A2 BR 112014010295 A2 BR112014010295 A2 BR 112014010295A2 BR 112014010295 A BR112014010295 A BR 112014010295A BR 112014010295 A BR112014010295 A BR 112014010295A BR 112014010295 A2 BR112014010295 A2 BR 112014010295A2
Authority
BR
Brazil
Prior art keywords
effective amount
hepatitis
virus
treatment
subject
Prior art date
Application number
BR112014010295A
Other languages
English (en)
Inventor
S Ray Adrian
M Hebner Christy
Mo Hongmei
Michelle Berrey Miriam
G Hindes Robert
T Symonds William
Original Assignee
Gilead Pharmassett Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Application filed by Gilead Pharmassett Llc filed Critical Gilead Pharmassett Llc
Publication of BR112014010295A2 publication Critical patent/BR112014010295A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

resumo métodos e composições para o tratamento de vírus de hepatite c é aqui revelado um método de tratamento de um sujeito infectado com o vírus da hepatite c, o referido método compreendendo a administração ao sujeito, por um período de tempo de uma quantidade eficaz de gm-7977 e uma quantidade eficaz de ribavirina. num aspecto, o método compreende a administração ao sujeito de um regime de tratamento livre de interferon que compreende uma quantidade eficaz de gm-7977 e uma quantidade eficaz de ribavirina. num aspecto particular, o método é suficiente para produzir uma quantidade não detectável de rna de hcv no sujeito durante pelo menos 12 semanas após o final do período de tempo. também é aqui revelada uma composição útil para o tratamento da infecção pelo vírus da hepatite c, compreendendo a referida composição uma quantidade eficaz de gm - 7977 e uma quantidade eficaz de ribavirina.
BR112014010295A 2011-10-31 2012-10-26 métodos e composições para o tratamento de vírus de hepatite c BR112014010295A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161553481P 2011-10-31 2011-10-31
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28
PCT/US2012/062115 WO2013066748A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
BR112014010295A2 true BR112014010295A2 (pt) 2017-04-18

Family

ID=48173020

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010295A BR112014010295A2 (pt) 2011-10-31 2012-10-26 métodos e composições para o tratamento de vírus de hepatite c

Country Status (10)

Country Link
EP (1) EP2776024A1 (pt)
JP (1) JP2014532657A (pt)
CN (1) CN104244947A (pt)
AR (1) AR088580A1 (pt)
AU (1) AU2012332827A1 (pt)
BR (1) BR112014010295A2 (pt)
CA (1) CA2853495A1 (pt)
TW (1) TW201318627A (pt)
UY (1) UY34420A (pt)
WO (1) WO2013066748A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141056A1 (es) 2011-09-16 2014-09-05 Gilead Pharmasset Llc Metodos para el tratamiento de vhc
MD4595B1 (ro) 2013-01-31 2018-10-31 Gilead Pharmasset Llc. Tabletă combinată conţinând doi compuşi antivirali
EA201692507A1 (ru) * 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические комбинации софосбувира и рибавирина
US20170151272A1 (en) * 2014-06-23 2017-06-01 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A novel pharmaceutical composition of sofosbuvir and ribavirin
WO2015197535A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
AU2015370004B2 (en) 2014-12-26 2021-03-11 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CZ2015443A3 (cs) * 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
CN106109538A (zh) * 2016-07-29 2016-11-16 桂林淮安天然保健品开发有限公司 治疗丙肝的药物组合物
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PT2061513E (pt) 2007-09-14 2011-10-17 Schering Corp Método para tratar doentes com hepatite c
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
JP2014510531A (ja) * 2011-03-31 2014-05-01 エフ．ホフマン−ラ ロシュ アーゲー Ｈｃｖ治療法の選択

Also Published As

Publication number Publication date
AR088580A1 (es) 2014-06-18
CA2853495A1 (en) 2013-05-10
UY34420A (es) 2013-05-31
AU2012332827A1 (en) 2014-05-15
WO2013066748A1 (en) 2013-05-10
CN104244947A (zh) 2014-12-24
JP2014532657A (ja) 2014-12-08
EP2776024A1 (en) 2014-09-17
TW201318627A (zh) 2013-05-16

Similar Documents

Publication Publication Date Title
BR112014010295A2 (pt) métodos e composições para o tratamento de vírus de hepatite c
BR112014012739A2 (pt) composições e métodos para o tratamento do vírus da hepatite c
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CY1119896T1 (el) Μεθοδοι για αγωγη toy hcv
JOP20170161A1 (ar) عوامل RNAi للعدوى بفيروس التهاب الكبد ب
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
ES2572329A2 (es) Combinacion de al menos dos agentes antivirales de accion directa y ribavirina pero no interferon, para uso en el tratamientodel vhc
BR112013022391A2 (pt) composições, métodos de tratamento e diagnóstico para o tratamento de esteatose hepática apenas ou em combinação com uma infecção pelo vírus da hepatite c e uso dessas composições
BR112015010461A2 (pt) usos alternativos para efetores da reunião do hbv
MY160130A (en) Hepatitis c virus inhibitors
EA202090514A1 (ru) Противовирусное средство против гепатита в
TN2012000358A1 (en) Hepatitis c virus inhibitors
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER
BR112012024661A2 (pt) composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
BR112013020042A2 (pt) inibidores de vírus da hepatite c
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
EA201300135A1 (ru) Комбинированная фармацевтическая композиция и способы лечения и профилактики инфекционных заболеваний
IN2012MN02896A (pt)
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
BR112022003698A2 (pt) Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica
NZ602552A (en) Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
ECSP21087299A (es) Composiciones y métodos para tratar el virus de la hepatitis c

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired